Selecting the optimal design for drug discontinuation trials in a setting of advanced, life-limiting illness [1]

JAMA Internal Medicine

Volumn 175, Issue 10, 2015, Pages 1724-1725

  Geijteman, Eric C T ^a,b   Tiemeier, Henning ^b   Van Gelder, Teun ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FRAIL ELDERLY; HUMAN; LETTER; LIFE EXPECTANCY; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; VALIDITY; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; FEMALE; MALE; NEOPLASM; PALLIATIVE THERAPY; PROCEDURES;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; COGNITION DISORDERS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASMS; PALLIATIVE CARE;

EID: 84943545110     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.3997     Document Type: Letter

References (5)

1. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691-700.
2. Holmes HM, Todd A. Evidence-based deprescribing of statins in patients with advanced illness. JAMA Intern Med. 2015;175(5):701-702.
3. Geijteman EC, van Gelder T, van Zuylen L. Sense and nonsense of treatment of comorbid diseases in terminally ill patients. JAMA Intern Med. 2015;175(3):346.
4. Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979;300 (22):1242-1245.
5. Adamson J, Cockayne S, Puffer S, Torgerson DJ. Review of randomised trials using the post-randomised consent (Zelen's) design. Contemp Clin Trials. 2006; 27(4):305-319.